VIDEO: Studies ‘fine tuning’ use of trastuzumab deruxtecan in breast cancer
Click Here to Manage Email Alerts
In this video, Paolo Tarantino, MD, discusses findings from DESTINY-Breast 04 presented at San Antonio Breast Cancer Symposium.
“One of the most striking advances in the field in the last year was the recognition that [fam-trastuzumab deruxtecan-nxki (T-DXd)], an antibody-drug conjugate targeting HER2, is not only very active in HER2-positive breast cancer, but also in HER2-low, which represents a very large population of patients,” Tarantino, a clinical research fellow at Dana-Farber Cancer Institute and at Harvard Medical School, told Healio.
He explained that researchers are “still fine-tuning” the use of this treatment in patients with HER2-low breast cancer, but that the results from the DESTINY-Breast04 trial showed that HER2 expression can predict the effectiveness of T-DXd (Enhertu; AstraZeneca, Daiichi Sankyo) in early and metastatic breast cancer.
“I believe that nowadays we don’t necessarily need to biopsy patients if they had a prior tumor that tested HER2-low either on the primary tumor or on an archival tissue on a prior biopsy, and this I think will help to use this agent in the clinic and to expand its benefit to all the patients who might benefit from targeting HER2 with T-DXd,” Tarantino said.
Collapse
Read more about
Click Here to Manage Email Alerts